NK-cell adoptive cell therapy (ACT) confers numerous advantages over T-cell ACT, including a lack of major histocompatibility complex (MHC) restriction, no need for prior sensitization, the activation of CD8+ T cells by inflammatory cytokines and a good safety profile with highly reduced graft versus host disease (GvHD) risk [8]. Here, CD8A is linked to graft versus host disease.